1. Home
  2. ATAI vs MTA Comparison

ATAI vs MTA Comparison

Compare ATAI & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • MTA
  • Stock Information
  • Founded
  • ATAI 2018
  • MTA 1983
  • Country
  • ATAI Germany
  • MTA Canada
  • Employees
  • ATAI N/A
  • MTA N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • MTA
  • Sector
  • ATAI Health Care
  • MTA
  • Exchange
  • ATAI Nasdaq
  • MTA Nasdaq
  • Market Cap
  • ATAI 444.7M
  • MTA 506.2M
  • IPO Year
  • ATAI 2021
  • MTA N/A
  • Fundamental
  • Price
  • ATAI $4.61
  • MTA $5.53
  • Analyst Decision
  • ATAI Strong Buy
  • MTA Hold
  • Analyst Count
  • ATAI 3
  • MTA 1
  • Target Price
  • ATAI $13.33
  • MTA $4.50
  • AVG Volume (30 Days)
  • ATAI 4.7M
  • MTA 913.3K
  • Earning Date
  • ATAI 11-12-2025
  • MTA 11-13-2025
  • Dividend Yield
  • ATAI N/A
  • MTA N/A
  • EPS Growth
  • ATAI N/A
  • MTA N/A
  • EPS
  • ATAI N/A
  • MTA N/A
  • Revenue
  • ATAI $2,309,000.00
  • MTA $8,167,999.00
  • Revenue This Year
  • ATAI $712.99
  • MTA $123.39
  • Revenue Next Year
  • ATAI N/A
  • MTA $64.87
  • P/E Ratio
  • ATAI N/A
  • MTA N/A
  • Revenue Growth
  • ATAI 510.85
  • MTA 70.70
  • 52 Week Low
  • ATAI $1.03
  • MTA $2.45
  • 52 Week High
  • ATAI $5.34
  • MTA $5.94
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 57.88
  • MTA 62.68
  • Support Level
  • ATAI $4.50
  • MTA $5.45
  • Resistance Level
  • ATAI $4.75
  • MTA $5.94
  • Average True Range (ATR)
  • ATAI 0.28
  • MTA 0.30
  • MACD
  • ATAI -0.04
  • MTA -0.02
  • Stochastic Oscillator
  • ATAI 50.33
  • MTA 47.44

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

Share on Social Networks: